Editorial: Prudent use of antibacterial agents: Are we entering in an era of infections with no effective antibacterial agents? What can we do?

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue 9, 2010, Pages 577-579

  Vila, Jordi ^a   Rodríguez Baño, Jesús ^b   Gargallo Viola, Domingo ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c Ferrer Grupo Research Center   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM; CEFTAROLINE; CEPHALOSPORIN DERIVATIVE; FOSFOMYCIN; QUINOLONE DERIVATIVE; TELAVANCIN; TRICLOSAN;

ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM CONTAMINATION; BLOODSTREAM INFECTION; DRUG INDUSTRY; EDITORIAL; GRAM POSITIVE INFECTION; HUMAN; INFECTION CONTROL; MULTIDRUG RESISTANCE; ANTIBIOTIC RESISTANCE; DRUG EFFECT; DRUG UTILIZATION; STANDARD;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; HUMANS;

EID: 77957597294     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2010.09.002     Document Type: Article

References (22)

1. C. Torres, M.A. Moreno, and M. Zaragoza Prudent use of antimicrobial agents: Not just for humans Enferm Infecc Microbiol Clin 2010 10.1016/j.eimc.2010.09.001
2. C. Ewers, M. Grobbel, I. Stamm, P.A. Kopp, I. Diehl, and T. Semmler Emergence of human pandemic O25:H4ST131 CTX-M-15 extended-spectrum-beta- lactamase-producing Escherichia coli among companion animals J Antimicrob Chemother 65 2010 651 660
3. M. Mellon, C. Benbrook, K.L. Benbrook, and I.T. Hogging Estimates of Antibacterial Abuse in Livestock 2001 Union of Concerned Scientists Cambridge, MA
4. S.B. Levy Antibacterial household products: cause for concern Emerg Infect Dis 7 2001 512 515
5. J. Vila, and T. Pal Update on antibacterial resistance in low-income countries: Factors favoring the emergence of resistance Open Infect Dis J 4 2010 38 54
6. J.D.D. Pitout, and K.B. Laupland Extended-spectrum β-lactamase- producing Enterobacteriaceae: an emerging public-health concern Lancet Infect Dis 8 2008 159 166
7. J. Rodrguez-Bao, and A. Pascual Clinical significance of extended-spectrum β-lactamases Expert Rev Anti Infect Therapy 6 2008 671 683
8. o estudio multicntrico (proyecto GEIH-BLEE 2006) Enferm Infecc Microbiol Clin 9 2009 503 510
9. J. Rodrguez-Bao, E. Picn, P. Gijn, J.R. Hernndez, M. Ruz, and C. Pea Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis Clin Infect Dis 50 2010 40 48
10. J. Rodrguez-Bao, and M.D. Navarro Impacto de las BLEE en los tratamientos empricos y las polticas antibiticas Enferm Infecc Microbiol Clin 25 extraordinario 2 2007 54 59
11. D.L. Paterson, and R.A. Bonomo Extended-spectrum β-lactamases: a clinical update Clin Microbiol Rev 18 2005 657 686
12. A.M. Queenan, and K. Bush Carbapenemases: the versatile β-lactamases Clin Microbiol Rev 20 2007 440 458
13. Y. Carmeli, M. Akova, G. Cornaglia, G.L. Daikos, J. Garau, and S. Harbarth Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control Clin Microbiol Infect 16 2010 102 111
14. M. Tato, T.M. Coque, O. Ruz-Garbajosa, V. Pintado, J. Cobo, and H.S. Sader Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-β-lactamase in Spain: toward endemicity? Clin Infect Dis 45 2007 1171 1178
15. T. Curiao, M.I. Morosini, P. Ruiz-Garbajosa, A. Robustillo, F. Baquero, and T.M. Coque Emergence of bla KPC-3-Tn4401a associated with a pKPN3/4-like plasmid within ST384 and ST388 Klebsiella pneumoniae clones in Spain J Antimicrob Chemother 65 2010 1608 1614
16. K.K. Kumarasamy, M.A. Toleman, T.R. Walsh, J. Bagaria, F. Butt, and R. Balakrishnan Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study Lancet Infect Dis 10 2010 597 602
17. J. Li, R.L. Nation, J.D. Turnidge, R.W. Milne, K. Coulthard, and C.R. Rayner Colistin: the re-emerging antibiotic for multidrug-resistant Gram negative bacterial infections Lancet Infect Dis 6 2006 589 601
18. M. Paul, J. Bishara, A. Levcovich, M. Chowers, E. Goldberg, and P. Singer Effectiveness and safety of colistin: prospective comparative cohort study J Antimicrob Chemother 65 2010 1019 1027
19. K. Vasilev, G. Reshedko, R. Orasan, M. Sanchez, J. Teras, and T. Babinchak A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae J Antimicrob Chemother 62 Suppl 1 2008 i29 i40
20. D.L. Higgins, R. Chang, D.V. Debabov, J. Leung, T. Wu, and K.M. Krause Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 49 2005 1127 1134
21. M.H. Kollef New antibacterial agents for methicillin-resistant Staphylococcus aureus Crit Care Resusc 11 2009 282 286
22. Infectious Diseases Society of America The 10 x '20 initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020 Clin Infect Dis 50 2010 1081 1084